This company develops genomic technology focused on improving the safety and characterization of gene editing tools for cell and gene therapies. Their INDUCE-seq platform enables developers to accurately detect on- and off-target edits associated with gene editing systems like CRISPR. This technology supports the standardization and acceleration of safer gene-edited therapeutic development.

Cairdac manufactures the ALPS™, the first autonomous leadless pacing system that utilizes inertial energy harvesting technology to power itself by capturing the heart's kinetic energy. This eliminates the need for battery replacements, addressing the significant longevity issues faced by traditional and leadless pacemakers.

Develops the CoFI System, a medical device that diagnoses microvascular obstruction (MVO) in real-time during percutaneous coronary interventions (PCI) using existing guide catheters and wires. It provides rapid, accurate detection of MVO, a condition affecting up to 60% of acute heart attack patients, and enables controlled delivery of therapeutic agents directly into the vasculature to improve patient outcomes.

SeqOne provides a clinical decision support platform that utilizes AI-driven bioinformatics to analyze next-generation sequencing (NGS) data for germline and somatic variants. The platform enhances diagnostic accuracy and efficiency by identifying complex genomic events that standard pipelines often overlook, thereby improving patient outcomes in precision medicine.